Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated at SVB Leerink

SVB Leerink assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research report released on Tuesday, MarketBeat Ratings reports. The firm issued an outperform rating and a $5.00 target price on the biopharmaceutical company’s stock.

Several other research firms have also issued reports on LXRX. Needham & Company LLC restated a hold rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, April 23rd. StockNews.com upgraded shares of Lexicon Pharmaceuticals to a sell rating in a report on Monday, April 15th.

Lexicon Pharmaceuticals Stock Performance

Shares of NASDAQ LXRX traded up $0.04 during midday trading on Tuesday, hitting $1.74. 5,858,774 shares of the company’s stock were exchanged, compared to its average volume of 4,359,358. Lexicon Pharmaceuticals has a twelve month low of $0.92 and a twelve month high of $3.79. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.60 and a quick ratio of 5.58. The firm has a market cap of $428.46 million, a P/E ratio of -2.17 and a beta of 1.38. The stock’s 50 day moving average price is $2.12 and its 200-day moving average price is $1.74.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.03. The business had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. Equities research analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of LXRX. TIAA Trust National Association purchased a new stake in Lexicon Pharmaceuticals in the 3rd quarter worth about $29,000. SG Americas Securities LLC acquired a new position in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at about $64,000. Swiss National Bank lifted its position in shares of Lexicon Pharmaceuticals by 4.4% in the third quarter. Swiss National Bank now owns 242,300 shares of the biopharmaceutical company’s stock worth $264,000 after purchasing an additional 10,300 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Lexicon Pharmaceuticals by 350.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 22,043 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its holdings in shares of Lexicon Pharmaceuticals by 160.9% during the third quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 24,400 shares during the period. Hedge funds and other institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.